Chromadex Corp.
(NASDAQ : CDXC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Process Industries » Chemicals Specialty
symbolcompany%chnglast%shortavg$volume
LINLinde Plc -0.10%308.450.0%$488.40m
DOWDow, Inc. 0.26%58.892.4%$388.13m
APDAir Products & Chemicals, Inc. 1.66%292.761.5%$323.69m
ALBAlbemarle Corp. -0.99%229.043.4%$242.55m
ECLEcolab, Inc. 0.34%220.101.6%$236.47m
LYBLyondellBasell Industries NV 0.83%99.152.8%$183.90m
AVTRAvantor, Inc. 2.18%38.360.0%$166.50m
DQDaqo New Energy Corp. 0.85%64.040.0%$105.68m
LTHMLivent Corp. 0.27%26.480.0%$76.08m
REGIRenewable Energy Group, Inc. -2.34%53.0019.6%$49.04m
GEVOGevo, Inc. -3.00%6.460.9%$48.82m
ASHAshland Global Holdings, Inc. -0.13%95.743.3%$45.98m
TROXTronox Holdings Plc 0.40%25.303.0%$41.83m
AMRSAmyris, Inc. -1.71%13.224.0%$40.25m
CHXChampionX Corp. 2.49%26.380.0%$39.98m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.